Search

Displaying results 6821 - 6830 of 9325 in total
  1. Drug

    (R)-Gossypol

    go.drugbank.com/drugs/DB17379
    Investigational

    (R)-Gossypol is the R-isomer of [Gossypol].

  2. Drug

    CL-315585

    go.drugbank.com/drugs/DB18758
    Experimental

    CL-315585 is the D isomer of [Verteporfin].

  3. Drug

    Rhein

    go.drugbank.com/drugs/DB13174
    Experimental

    It is known to have hepatoprotective, nephroprotective, anti-cancer, anti-inflammatory, and several other protective effects.

  4. Drug

    Talactoferrin alfa

    go.drugbank.com/drugs/DB05426
    Investigational

    It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

  5. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  6. Drug

    Resiniferatoxin

    go.drugbank.com/drugs/DB06515
    Investigational

    Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission

  7. Drug

    JNJ-26489112

    go.drugbank.com/drugs/DB15203
    Investigational

    JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive

  8. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  9. Drug

    BN‐Brachyury vaccine

    go.drugbank.com/drugs/DB17425
    Experimental

    It is composed of the [MVA-BN-brachyury-TRICOM vaccine] and the fowlpox virus(FPV)‐Brachyury booster vaccine.[A255173]

  10. Drug

    Pamufetinib

    go.drugbank.com/drugs/DB20752
    Investigational

    The usage of the INN stem '-tinib' in the name indicates that Pamufetinib is a tyrosine kinase inhibitor. Pamufetinib is under investigation in clinical trial NCT04999761 (AB122 Platform Study).